Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 26INDUSTRY 4OTHER_GOV 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Head & Neck 3Other solid neoplasm 2Endocrine 2Other hematologic neoplasm 1

Conditions

Colorectal Neoplasms 2Stomach Neoplasms 1Esophageal Neoplasms 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × donafenib × Gastrointestinal × Clear all
NCT02489201 2023-06-15

A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Terminated
19 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT02489214 2023-05-08

Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Terminated
13 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02870582 2022-11-29

Donafenib for Previously Treated Metastatic Colorectal Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Completed
536 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02489916 2016-01-05

Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Completed
47 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡